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ABackground: Difficult-to-treat palmoplantar psoriasis has a disproportionately negative impact onquality of life.Objective: We evaluated the efficacy and safety of apremilast in palmoplantar psoriasis.Methods: A post hoc analysis of data pooled from phase IIb (PSOR-005) and phase III (Efficacy and Safety
Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1 and 2) clinical studies was conducted to
determine the effect of apremilast 30 mg twice daily versus placebo at week 16 in a subset of patients with
moderate to severe plaque psoriasis with active palmoplantar psoriasis (baseline Palmoplantar Psoriasis
Physician Global Assessment [PPPGA] score $1).Results: Significantly more patients taking apremilast with moderate to severe palmoplantar psoriasis
(baseline PPPGA score $3) achieved PPPGA score 0 (clear) or 1 (almost clear) compared with placebo at
week 16 (48% vs 27%; P = .021). At week 16, 46% of the apremilast group with baseline PPPGA score 1 or
higher achieved a PPPGA score of 0 versus 25% of the placebo group (P\.001); 59% of the apremilast group
had a PPPGA score of 0 or 1 with 1-point or more improvement versus 39% receiving placebo (P\ .001).Limitations: This post hoc analysis was limited to 16 weeks and did not assess palmoplantar pustules,
lesion localization, or surface area involvement.Conclusion: Apremilast may be a useful oral treatment option for patients with moderate to severe
palmoplantar plaque psoriasis. ( J Am Acad Dermatol 2016;75:99-105.)Innovaderm Research Inc, Montreala; Eastern Virginia
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d Palmoplantar psoriasis can be difficult
to treat.
d Apremilast 30 mg twice daily
significantly reduced the severity of
palmoplantar psoriasis at week 16.
d Apremilast may be a useful oral
treatment option for patients with
palmoplantar psoriasis.Psoriasis is a chronic sys-
temic inflammatory disease
characterized by dysregu-
lated immune responses,
with an imbalance in the
production
of proinflammatory and anti-
inflammatory cytokines.1,2
Palmoplantar plaque psoria-
sis is localized to the palms
and/or soles and character-
ized by well-defined red,
scaly plaques or thickening/
scaling without redness that
may or may not include pustules.3 Its reported
prevalence among patients with psoriasis ranges
widely, from 6% to 17%.4,5 Palmoplantar pustulosis
may occur in patients with or without chronic pso-
riasis or palmoplantar lesions and is characterized by
presence of erupting sterile pustules on the palms
and soles, resulting in hyperkeratosis, erythema, and
fissuring of the skin.3,6 The existence of palmoplan-
tar pustulosis as a distinct condition in patients with
chronic psoriasis remains controversial.
Palmoplantar plaque psoriasis is difficult to treat
as shown by its varying responsiveness to treat-
ments.4,7-9 Patients with plaque psoriasis and
palmoplantar psoriasis have greater functional
disability and decrements in health-related quality
of life compared with patients with plaque
psoriasis lesions located elsewhere on the body.4,10
Patients with palmoplantar psoriasis report greater
impairment of mobility, self-care activities, and usual
activities, and greater dependency on topical
medications.10 Treatment of this type of psoriasis is
often empirical because of the limited clinical
trial data available in this population, and involves
topical and ultraviolet therapy, which have limited
effectiveness.11
Phosphodiesterase-4 is an enzyme that regulates
levels of cyclic adenosine monophosphate, a key
modulator of immune cell responses.12 Apremilast
is an oral small molecule phosphodiesterase-4
inhibitor that works intracellularly within immune
cells to regulate the production of inflammatory
mediators, such as interleukin (IL)-17, tumor
necrosis factor-alfa, IL-23, and anti-inflammatory
mediators implicated in the pathogenesis of
psoriasis.13 Apremilast has demonstrated efficacy
in the treatment of moderate to severe plaque
psoriasis in the Efficacy and Safety Trial Evaluatingthe Effects of Apremilast
in Psoriasis (ESTEEM) phase
III clinical trial program,
comprising 2 randomized,
placebo-controlled studies
that evaluated the efficacy,
safety, and tolerability of
apremilast in more than
1200 patients with moderate
to severe plaque psoriasis for
up to 52 weeks.14,15 In these
studies, apremilast demon-
strated statistically significant
and clinically meaningful im-provements, as measured by 75% reduction from
baseline in Psoriasis Area and Severity Index (PASI)
score at week 16 (primary end point). Improvements
were observed at week 16 in difficult-to-treat areas
such as the nail and scalp.16 Based on findings from
the apremilast clinical trial program, including the
results of the ESTEEM studies, apremilast was
approved by the US Food and Drug Administration
in September 2014 and by the European Commission
in January 2015 for moderate to severe plaque
psoriasis.17,18
Here, we report the findings from a post hoc
analysis of the phase IIb PSOR-005 and phase III
ESTEEM clinical trials examining the effect of
apremilast at week 16 in a pooled subset of patients
with palmoplantar plaque psoriasis.
METHODS
Study design and participants
PSOR-005 (NCT00773734) was a multicenter,
randomized, placebo-controlled, dose-ranging study
conducted at 35 US and Canadian sites between
September 24, 2008, andOctober 21, 2009. ESTEEM 1
(NCT01194219) and ESTEEM 2 (NCT01232283)
were similarly designed phase III, multicenter,
randomized, double-blind, placebo-controlled
studies; ESTEEM 1 was conducted from September
2010 to December 2012 at 72 sites in Australia,
Belgium, Canada, France, Germany, Italy, the
United Kingdom, and the United States, and
ESTEEM 2 was conducted from November 2010 to
December 2012 at approximately 40 sites in Austria,
Canada, Denmark, France, Germany, Italy, Spain,
Switzerland, and the United States. Full details of the
study designs, inclusion and exclusion criteria,
patient populations, and primary safety and efficacy
results for PSOR-005, ESTEEM 1, and ESTEEM 2 have
Abbreviations used:
ESTEEM: Efficacy and Safety Trial Evaluating the
Effects of Apremilast in Psoriasis
IL: interleukin
m-PPPASI: modified Palmoplantar Psoriasis Area
and Severity Index
PASI: Psoriasis Area and Severity Index
PGA: Physician Global Assessment
PPPGA: Palmoplantar Psoriasis Physician
Global Assessment
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studies provided written informed consent before
study-related procedures were done, and the proto-
col and consent were approved by institutional
review boards or ethics committees at all investiga-
tional sites. Each study was conducted in accordance
with the principles of Good Clinical Practice and the
Declaration of Helsinki.
PSOR-005, ESTEEM 1, and ESTEEM 2 enrolled
patients aged 18 years or older with moderate to
severe psoriasis at screening and baseline, defined as
a PASI score 12 or higher, psoriasis body surface area
involvement 10% ormore, and static Physician Global
Assessment (PGA) score 3 or higher (moderate to
severe; ESTEEM 1 and 2 only).14,15,19 All 3 studies
enrolled patients who were considered candidates
for phototherapy or systemic therapy. Patients with
a history of phototherapy or systemic treatment
(small molecule or biologic), including failures,
were eligible to participate. There were no specific
inclusion or exclusion criteria related to palmoplantar
psoriasis involvement for any of the 3 studies.
Palmoplantar psoriasis efficacy assessments
For all 3 studies, palmoplantar involvement was
measured using the Palmoplantar Psoriasis PGA
(PPPGA) with a 5-point scale (0 = clear, defined as
no signs of plaque psoriasis on hands and/or feet;
1 = almost clear, defined as just perceptible erythema
and just perceptible scaling on the hands and/or feet;
2 = mild, defined as light-pink erythemawith minimal
scalingwith or without pustules on hands and/or feet;
3 = moderate, defined as dull-red, clearly distinguish-
able erythema with diffuse scaling and thickening of
the skin, with or without fissures, and with or without
pustule formation on the hands and/or feet; and
4 = severe, defined as deep-/dark-red erythema with
clearly obvious and diffuse scaling and thickening,
and numerous fissures with or without pustule
formation on the hands and/or feet). Information on
the type of palmoplantar disease (ie, pustular vs
nonpustular) was not collected. PPPGA assessments
were obtained at baseline for all patients, and post-
baseline among patients with a baseline PPPGA score1 or higher at weeks 2, 4, 8, 12, and 16. The proportion
of patients with a PPPGA score 3 or higher at baseline
who achieved a PPPGA rating of 0 or 1 atweek 16was
determined. Additional post hoc analyses were
performed among patients with PPPGA score 1 or
higher at baseline and included the proportion who
achieved: (1) a PPPGA score of 0 at week 16, and (2) a
PPPGA score of 0 or 1 with 1-point or more
improvement at week 16.
Safety assessments
Safety assessments included collection of
adverse events, vital signs, laboratory evaluations,
physical examinations, chest radiographs, and
electrocardiograms.
Statistical analysis
Post hoc efficacy analyses of palmoplantar psori-
asis included data pooled fromPSOR-005, ESTEEM 1,
and ESTEEM 2 for all patients randomized to
placebo or apremilast 30 mg twice daily who met
either of the PPPGA criteria for the different analyses
(PPPGA score $3 at baseline or PPPGA score $1 at
baseline). For each PPPGA response category,
comparisons between the placebo and apremilast
groups were performed using a Fisher exact test,
with a 2-sided type 1 error set at .05; missing values
were handled using nonresponder imputation.
Safety analyses included all randomized patients
with a PPPGA score 1 or higher at baseline who
received 1 or more doses of study drug.
RESULTS
Patients
A total of 427 patients in the phase IIb PSOR-005
and phase III ESTEEM 1 and 2 studies had palmo-
plantar psoriasis at baseline (ie, PPPGA score $1)
(Fig 1), representing 29.8%of all patients randomized
to placebo or apremilast 30mg twice daily at baseline
in the studies (N = 1431). Among these patients,
moderate to severe palmoplantar psoriasis
(PPPGA score $3) was present in 144 patients
(10.1%) at baseline. Patient demographics, disease
characteristics, and severity of palmoplantar psoriasis
were generally balanced between the placebo and
apremilast groups with a PPPGA score 1 or higher at
baseline (Table I). In comparison with the patient
populations for each study described previ-
ously,14,15,19 the current pooled subpopulation with
palmoplantar psoriasis of any severity appeared to
comprise a greater proportion of male patients and a
slightly greater proportion with severe psoriasis. In
addition, 45% of the current pooled subpopulation
with palmoplantar psoriasis of any severity were
smokers or had a history of smoking (Table I).
Table I. Baseline demographics and disease characteristics for all randomized patients with a Palmoplantar
Psoriasis Physician Global Assessment score 1 or higher at baseline
Pooled phase II PSOR-005 and phase III ESTEEM 1 and 2 studies
Placebo
n = 153
Apremilast 30 mg twice daily
n = 274
Total
N = 427
Age, mean (SD), y 47.8 (12.71) 45.0 (13.07) 46.0 (13.00)
Male, n (%) 119 (77.8) 196 (71.5) 315 (73.8)
White, n (%) 141 (92.2) 239 (87.2) 380 (89.0)
Body mass index, mean (SD), kg/m2 30.7 (7.16) 30.0 (6.40) 30.3 (6.68)
Tobacco use, current or past, n (%) 62 (40.5) 130 (47.4) 192 (45.0)
Duration of plaque psoriasis, mean (SD), y 19.4 (12.78) 18.5 (11.79) 18.9 (12.14)
PASI score, mean (SD) 20.9 (7.54) 20.7 (8.87) 20.7 (8.41)
PASI score[20, n (%) 66 (43.1) 103 (37.6) 169 (39.6)
Body surface area, mean (SD), % 27.4 (14.88) 28.7 (17.89) 28.2 (16.86)
Body surface area[20%, n (%) 92 (60.1) 154 (56.2) 246 (57.6)
sPGA of 4 [severe], n (%) 64 (41.8) 91 (33.2) 155 (36.3)
History of nail psoriasis, n (%) 126 (82.4) 217 (79.2) 343 (80.3)
History of palmoplantar psoriasis, n (%) 112 (73.2) 193 (70.4) 305 (71.4)
PPPGA score, n (%)
1, Almost clear 40 (26.1) 78 (28.5) 118 (27.6)
2, Mild 61 (39.9) 104 (38.0) 165 (38.6)
3, Moderate 46 (30.1) 73 (26.6) 119 (27.9)
4, Severe 6 (3.9) 19 (6.9) 25 (5.9)
Prior phototherapy, n (%) 40 (26.1) 83 (30.3) 123 (28.8)
Prior conventional systemic therapy, n (%) 60 (39.2) 99 (36.1) 159 (42.7)
Prior biologic therapy, n (%) 42 (27.4) 70 (25.5) 112 (26.2)
n = Number of randomized patients; actual number of patients available for each parameter may vary.
ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; PASI, Psoriasis Area and Severity Index; PPPGA, Palmoplantar
Psoriasis Physician Global Assessment; sPGA, static Physician Global Assessment.
Fig 1. Patient disposition for the PSOR-005, Efficacy and Safety Trial Evaluating the Effects of
Apremilast in Psoriasis (ESTEEM ) 1, and ESTEEM 2 clinical studies. PPPGA, Palmoplantar
Psoriasis Physician Global Assessment.
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Fig 2. Achievement of Palmoplantar Psoriasis Physician
Global Assessment (PPPGA) score of 0 (clear) or 1 (almost
clear) at week 16 in patients with a PPPGA score 3 or
higher at baseline, indicating moderate or severe
palmoplantar psoriasis. Missing values were handled using
nonresponder imputation. n/N, number of patients with
response/sufficient data for evaluation. *P = .021 by Fisher
exact test versus placebo.
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At week 16, significantly more patients with a
PPPGA score 3 or higher at baseline achieved a
PPPGA score of 0 or 1 with apremilast compared
with placebo (48% [44 of 92] vs 27% [14 of 52],
respectively; 95% confidence interval 0.05-0.37;
P = .021) (Fig 2). The effect of apremilast 30 mg
twice daily on palmoplantar psoriasis in a patient
with a baseline PPPGA score of 3 (moderate) who
achieved PPPGA score of 0 (clear) after 16 weeks of
treatment is shown in Fig 3.
At week 16, 46% (127 of 274) of patients receiving
apremilast who had a PPPGA score 1 or higher at
baseline achieved a PPPGA score of 0 comparedwith
25% (39 of 153) receiving placebo (95% confidence
interval 0.12-0.30; P\ .001) (Fig 4). Among patients
with a PPPGA score 1 or higher at baseline, 59% (162
of 274) receiving apremilast had a PPPGA score of
0 or 1 with 1-point or more improvement at week 16
compared with 39% (60 of 153) receiving placebo
(95% confidence interval 0.10-0.30; P\.001) (Fig 5).
Safety
Patients with PPPGA score 1 or higher at baseline
who received 1 or more doses of study drug were
included in the safety analysis (placebo: n = 152;
apremilast 30 mg twice daily: n = 273); 2 patients
(ESTEEM1: n = 1; ESTEEM2: n = 1) did not receive the
study drug and were not included in the safety
analysis. Among patients with palmoplantar psoriasis
at baseline, most adverse events with apremilast were
mild to moderate in nature and severity. Common
adverse events occurring in 5% or more of patients
receiving apremilast included diarrhea, nausea, upper
respiratory tract infection, nasopharyngitis, vomiting,
tension headache, and headache (Table II). No case
of cellulitis was reported in any patient.DISCUSSION
The current findings indicate that palmoplantar
involvement may be far more prevalent than previ-
ously described among patients with moderate to
severe plaque psoriasis (overall body surface area
involvement$10%).5,8,9 In the pooled population of
PSOR-005, ESTEEM 1, and ESTEEM 2, 29.8% of all
randomized patients had some palmoplantar
involvement at baseline, and 10.1% of patients had
moderate to severe palmoplantar disease. Baseline
patient demographics and disease characteristics of
the palmoplantar cohort were generally similar to
those of the intent-to treat population in the primary
analyses, although there appeared to be slightly
higher proportions of male patients and those with
severe disease.14,15,19 The fairly high prevalence of
palmoplantar involvement here differs sharply from
reports indicating that it is seen in only a small subset
of patients (5%-18%) who have psoriasis plaques on
other areas of the body.5,8,9 Important differences in
patient selection criteria across some of these earlier
studies and the current studies likely play a role in
the differing prevalence and clinical characteristics of
the palmoplantar psoriasis cases described.
In this pooled post hoc analysis of the PSOR-005,
ESTEEM 1, and ESTEEM 2 clinical studies, treatment
with apremilast was associated with a significant
improvement in moderate to severe palmoplantar
psoriasis at week 16 compared with placebo.
Apremilast treatment resulted in the achievement of
PPPGA ratings of 0 (clear) or 1 (almost clear) by 48%
of patients with moderate to severe palmoplantar
psoriasis and more than half (59%) of patients with
palmoplantar psoriasis of any severity at baseline
with 1-point or more improvement. Consistent with
the safety profile observed for the intent-to-treat
populations in the primary analyses, apremilast was
generally well tolerated and the most common
infections among the subset of patients with
palmoplantar psoriasis were upper respiratory tract
infection and nasopharyngitis.14,15,19
There is a paucity of data available regarding the
treatment of palmoplantar psoriasis.20 The current
findings compare favorably with those from a
placebo-controlled study described by Leonardi
et al,7 where 31% of patients with psoriasis largely
(although not exclusively) limited to the palmoplan-
tar regions achieved a PPPGA score of 0 or 1 after
16 weeks of adalimumab treatment, compared with
4% of patients receiving placebo (P = .01). They also
compare favorably with findings from Gottlieb
et al,21 who reported that 33.3% of patients with
moderate to severe palmoplantar psoriasis treated
with secukinumab achieved a PPPGA score of 0 or 1
at week 16, comparedwith 1.5% of patients receiving
Fig 3. Effect of apremilast 30 mg twice daily in a patient with palmoplantar psoriasis at baseline
(Palmoplantar Psoriasis Physician Global Assessment [PPPGA] score = 3) (A) and week 16
(PPPGA score = 0) (B).
Fig 4. Achievement of Palmoplantar Psoriasis Physician
Global Assessment (PPPGA) score of 0 (clear) at week 16
in patients with a PPPGA score 1 or higher at baseline,
indicating the presence of any palmoplantar psoriasis.
*P\.001 by Fisher exact test versus placebo. BID, Twice a
day.
Fig 5. Achievement of Palmoplantar Psoriasis Physician
Global Assessment (PPPGA) score of 0 (clear) or 1 (almost
clear) with 1-point or more improvement at week 16 in
patients with a PPPGA score 1 or higher at baseline,
indicating the presence of any palmoplantar psoriasis.
*P\ .001 by Fisher exact test versus placebo. BID, Twice
a day.
Table II. Adverse events reported in 5% or more of
patients in any treatment group during the
placebo-controlled period (weeks 0-16) in the
pooled safety population of patients with
Palmoplantar Psoriasis Physician Global Assessment
score 1 or higher at baseline
Patients, n (%)
Placebo
n = 152
Apremilast
30 mg twice daily
n = 273
Diarrhea 9 (5.9) 53 (19.4)
Upper respiratory tract infection 8 (5.3) 28 (10.3)
Nausea 9 (5.9) 44 (16.1)
Vomiting 2 (1.3) 18 (6.6)
Nasopharyngitis 11 (7.2) 23 (8.4)
Tension headache 6 (3.9) 23 (8.4)
Headache 5 (3.3) 14 (5.1)
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in patients with palmoplantar psoriasis ($10%
surface area of palms or soles and modified
Palmoplantar PASI [m-PPPASI] score $8), 33.3%achieved a 75% or greater reduction from baseline
in m-PPPASI score after 14 weeks of infliximab
treatment; at week 26, 29.1% achieved 90% or greater
reduction from baseline in m-PPPASI score.22
Similarly, about one quarter to one third of patients
have been reported to achieve 75% or greater
reduction from baseline in m-PPPASI score with
conventional systemic agents such as methotrexate8
or phototherapy23; 42% achieved such response with
paint psoralen plus ultraviolet A.23 Published data
with etanercept and ustekinumab in nonpustular
palmoplantar psoriasis are limited to case reports
and small, open-label investigator-initiated trials.20,24
An investigator-initiated study reported by Au et al24
evaluated ustekinumab in 20 patients with palmo-
plantar psoriasis. After 16 weeks of treatment with
ustekinumab, clinical clearance, defined as a
PalmeSole PGA score of 0 or 1 based on a 6-point
scale, was achieved by 7 of 20 patients (35%), which
is in alignment with findings from the previously
discussed placebo-controlled studies of other bio-
logic agents. It should be noted that interpretation of
J AM ACAD DERMATOL
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use of different palmoplantar assessment scales and
end points, different treatment periods, and widely
varying patient selection criteria. These studies and
the current analysis, nevertheless, suggest that the
oral phosphodiesterase-4 inhibitor apremilast may
be an effective alternative to other available agents
for patients with palmoplantar psoriasis in the
context of moderate to severe psoriasis.
Interpretation of these findings is limited by the
exploratory nature of the analyses and short-term
16-week placebo-controlled treatment period. In
addition, none of the apremilast studies assessed the
percentageofpsoriasis body surface area involvement
or localization of lesions on the palms and soles in
patientswithpalmoplantar psoriasis, nordid theynote
pustular versus nonpustular forms. Patients included
in the pooled post hoc analysis were required to have
some form of involvement on the palm, sole, or both
but could have very limited psoriatic surface area
involvement of the hands and feet.
In conclusion, apremilast was well tolerated and
demonstrated efficacy in patients with moderate to
severe palmoplantar psoriasis. Further studies,
including studies in patients with extensive and
severe palmoplantar psoriasis, are warranted to
confirm these findings.
The authors would like to thank Irina Khanskaya, John
Marcsisin, Claire Barcellona (clinical); Zuoshun Zhang
(statistics); Monica Bilbault, Dale McElveen (clinical
operations); Marlene Kachnowski (data management);
Ann Marie Tomasetti, Trisha Zhang (programming); and
Kamal Shah (safety) of Celgene Corporation for their
contributions to the study and/or the manuscript.
REFERENCES
1. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and
therapy of psoriasis. Nature. 2007;445:866-873.
2. Coimbra S, Figueiredo A, Castro E, Rocha-Pereira P,
Santos-Silva A. The roles of cells and cytokines in the
pathogenesis of psoriasis. Int J Dermatol. 2012;51:389-398.
3. Brunasso AM, Puntoni M, Aberer W, Delfino C, Fancelli L,
Massone C. Clinical and epidemiological comparison of
patients affected by palmoplantar plaque psoriasis and
palmoplantar pustulosis: a case series study. Br J Dermatol.
2013;168:1243-1251.
4. Adisen E, Tekin O, Gulekon A, Gurer MA. A retrospective
analysis of treatment responses of palmoplantar psoriasis in
114 patients. J Eur Acad Dermatol Venereol. 2009;23:814-819.
5. Kumar B, Saraswat A, Kaur I. Palmoplantar lesions in psoriasis:
a study of 3065 patients. Acta Derm Venereol. 2002;82:192-195.
6. Sevrain M, Richard MA, Barnetche T, et al. Treatment for
palmoplantar pustular psoriasis: systematic literature review,
evidence-based recommendations and expert opinion. J Eur
Acad Dermatol Venereol. 2014;28(Suppl 5):13-16.
7. Leonardi C, Langley RG, Papp K, et al. Adalimumab for
treatment of moderate to severe chronic plaque psoriasis of
the hands and feet: efficacy and safety results from REACH, arandomized, placebo-controlled, double-blind trial. Arch Der-
matol. 2011;147:429-436.
8. Janagond AB, Kanwar AJ, Handa S. Efficacy and safety
of systemic methotrexate vs. acitretin in psoriasis patients with
significant palmoplantar involvement: a prospective, random-
ized study. J Eur Acad Dermatol Venereol. 2013;27:e384-e389.
9. Takahashi MD, Chouela EN, Dorantes GL, et al. Efalizumab in
the treatment of scalp, palmoplantar and nail psoriasis: results
of a 24-week Latin American study. Arch Drug Inf. 2010;3:1-8.
10. Chung J, Callis Duffin K, Takeshita J, et al. Palmoplantar
psoriasis is associated with greater impairment of
health-related quality of life compared with moderate to
severe plaque psoriasis. J Am Acad Dermatol. 2014;71:623-632.
11. Marsland AM, Chalmers RJ, Hollis S, Leonardi-Bee J,
Griffiths CE. Interventions for chronic palmoplantar pustulosis.
Cochrane Database Syst Rev. 2006;(1):CD001433.
12. Houslay MD, Schafer P, Zhang KY. Keynote review:
phosphodiesterase-4 as a therapeutic target. Drug Discov
Today. 2005;10:1503-1519.
13. Schafer PH, Parton A, Capone L, et al. Apremilast is a selective
PDE4 inhibitor with regulatory effects on innate immunity. Cell
Signal. 2014;26:2016-2029.
14. Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral
phosphodiesterase 4 (PDE4) inhibitor, in patients with
moderate to severe plaque psoriasis: results of a phase III,
randomized, controlled trial (Efficacy and Safety Trial
Evaluating the Effects of Apremilast in Psoriasis [ESTEEM 1]).
J Am Acad Dermatol. 2015;73:37-49.
15. Paul C, Cather J, Gooderham M, et al. Efficacy and safety of
apremilast, an oral phosphodiesterase 4 inhibitor, in patients
with moderate to severe plaque psoriasis over 52 weeks: a
phase III, randomized, controlled trial (ESTEEM 2). Br J
Dermatol. 2015;173:1387-1399.
16. Rich P, Gooderham M, Bachelez H, et al. Apremilast, an oral
phosphodiesterase 4 inhibitor, in patients with
difficult-to-treat nail and scalp psoriasis: results of 2 phase III
randomized, controlled trials (ESTEEM 1 and ESTEEM 2). J Am
Acad Dermatol. 2016;74:134-142.
17. Otezla [package insert]. Summit, NJ: Celgene Corporation;
September 2014.
18. Otezla [summary of product characteristics]. Uxbridge, United
Kingdom: Celgene Europe Ltd; 2015.
19. Papp K, Cather JC, Rosoph L, et al. Efficacy of apremilast in the
treatment of moderate to severe psoriasis: a randomized
controlled trial. Lancet. 2012;380:738-746.
20. Sanchez-Regana M, Aldunce Soto MJ, Belinchon Romero I,
et al. Evidence-based guidelines of the Spanish psoriasis
group on the use of biologic therapy in patients with psoriasis
in difficult-to-treat sites (nails, scalp, palms, and soles). Actas
Dermosifiliogr. 2014;105:923-934.
21. Gottlieb AB, Sullivan J, van DoornMB. Secukinumab is effective in
subjectswithmoderate to severepalmoplantar psoriasis: 16week
results from the GESTURE study. Presented at: World Congress of
Dermatology Vancouver, BC, Canada. June 8-13, 2015.
22. Bissonnette R, Poulin Y, Guenther L, Lynde CW, Bolduc C,
Nigen S. Treatment of palmoplantar psoriasis with infliximab: a
randomized, double-blind placebo-controlled study. J Eur
Acad Dermatol Venereol. 2011;25:1402-1408.
23. Lozinski A, Barzilai A, Pavlotsky F. Broad-band UVB
versus paint PUVA for palmoplantar psoriasis treatment.
J Dermatolog Treat. 2016;27(3):221-223.
24. Au SC, Goldminz AM, Kim N, et al. Investigator-initiated,
open-label trial of ustekinumab for the treatment of
moderate-to-severe palmoplantar psoriasis. J Dermatolog
Treat. 2013;24:179-187.
